Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3013% below fair value
$150.57−6.02 (-3.84%)
Close on Nov 20, 2026Market cap $15.31BP/E 22.1Yield –
Neurocrine Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Neurocrine Biosciences's revenue for the twelve months ending Jun 30, 2026 was $3.37B, up 34.4% year over year. For fiscal 2025 it was $2.86B, up 21.4% from the year before. Over ten years it grew 64.5% a year on average. The highest annual figure on record is $2.86B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | +21.4% |
| FY2024 | Dec 31, 2024 | $2.36B | +24.8% |
| FY2023 | Dec 31, 2023 | $1.89B | +26.8% |
| FY2022 | Dec 31, 2022 | $1.49B | +31.3% |
| FY2021 | Dec 31, 2021 | $1.13B | +8.4% |
| FY2020 | Dec 31, 2020 | $1.05B | +32.7% |
| FY2019 | Dec 31, 2019 | $788.10M | +74.7% |
| FY2018 | Dec 31, 2018 | $451.20M | +179.2% |
| FY2017 | Dec 31, 2017 | $161.63M | +977.5% |
| FY2016 | Dec 31, 2016 | $15.00M | -24.1% |
| FY2015 | Dec 31, 2015 | $19.77M | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $2.92M | -94.5% |
| FY2012 | Dec 31, 2012 | $53.14M | -31.4% |
| FY2011 | Dec 31, 2011 | $77.41M | +131.1% |
| FY2010 | Dec 31, 2010 | $33.50M | +1034.5% |
| FY2009 | Dec 31, 2009 | $2.95M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $959.00M | +39.5% |
| Q1 FY2026 | Mar 31, 2026 | $814.50M | +42.2% |
| Q4 FY2025 | Dec 31, 2025 | $805.50M | +28.3% |
| Q3 FY2025 | Sep 30, 2025 | $794.90M | +27.8% |
| Q2 FY2025 | Jun 30, 2025 | $687.50M | +16.5% |
| Q1 FY2025 | Mar 31, 2025 | $572.60M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $627.70M | +21.8% |
| Q3 FY2024 | Sep 30, 2024 | $622.10M | +24.7% |
| Q2 FY2024 | Jun 30, 2024 | $590.20M | +30.4% |
| Q1 FY2024 | Mar 31, 2024 | $515.30M | +22.6% |
| Q4 FY2023 | Dec 31, 2023 | $515.20M | +25.0% |
| Q3 FY2023 | Sep 30, 2023 | $498.80M | +28.6% |
| Q2 FY2023 | Jun 30, 2023 | $452.70M | +19.7% |
| Q1 FY2023 | Mar 31, 2023 | $420.40M | +35.4% |
| Q4 FY2022 | Dec 31, 2022 | $412.00M | +32.1% |
| Q3 FY2022 | Sep 30, 2022 | $387.90M | +31.0% |
| Q2 FY2022 | Jun 30, 2022 | $378.20M | +30.9% |
| Q1 FY2022 | Mar 31, 2022 | $310.60M | +31.3% |
| Q4 FY2021 | Dec 31, 2021 | $312.00M | +25.9% |
| Q3 FY2021 | Sep 30, 2021 | $296.00M | +14.5% |
| Q2 FY2021 | Jun 30, 2021 | $288.90M | -4.5% |
| Q1 FY2021 | Mar 31, 2021 | $236.60M | -0.2% |
| Q4 FY2020 | Dec 31, 2020 | $247.90M | +1.6% |
| Q3 FY2020 | Sep 30, 2020 | $258.50M | +16.4% |
| Q2 FY2020 | Jun 30, 2020 | $302.40M | +64.8% |
| Q1 FY2020 | Mar 31, 2020 | $237.10M | +71.3% |
| Q4 FY2019 | Dec 31, 2019 | $244.10M | +85.6% |
| Q3 FY2019 | Sep 30, 2019 | $222.10M | +46.4% |
| Q2 FY2019 | Jun 30, 2019 | $183.50M | +89.4% |
| Q1 FY2019 | Mar 31, 2019 | $138.40M | +94.7% |
| Q4 FY2018 | Dec 31, 2018 | $131.49M | +39.1% |
| Q3 FY2018 | Sep 30, 2018 | $151.76M | +149.7% |
| Q2 FY2018 | Jun 30, 2018 | $96.91M | +1429.7% |
| Q1 FY2018 | Mar 31, 2018 | $71.09M | – |
| Q4 FY2017 | Dec 31, 2017 | $94.52M | – |
| Q3 FY2017 | Sep 30, 2017 | $60.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $6.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?